Generic filters
Filter by content type
Taxonomy terms

SYBX – Synlogic Inc


Subscribe for full access

Unlock Industry-grade Shariah Compliance for US, UK, Canada, Germany, GCC, Europe and India. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.

Get started from just $1/month


Recommendation Rating







1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Analysts’ Price Targets

Mean 7.6

Low: 6

High: 9

Total Analysts: 4

Company Profile

Synlogic, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of synthetic biology therapeutics for the treatment of rare, infectious, and other diseases. Its pipeline includes its lead program in phenylketonuria (PKU). The Company’s PKU program includes two development candidates, SYNB1618 and SYNB1934. SYNB1618 and SYNB1934 are orally administered, non-systemically absorbed drug candidates for PKU, which is a genetic disease caused by neurotoxic levels of the amino acid Phe. Its product pipeline includes SYNB1353 and SYNB8802. SYNB1353 is an orally administered, non-systemically absorbed live biotherapeutic drug candidate engineered to consume methionine in the gastrointestinal tract (GI) total homocysteine (tHcy) in homocystinuria (HCU) patients and allowing natural protein intake. SYNB8802 is a non-systemically absorbed drug candidate developed for the treatment of enteric hyperoxaluria.

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan